ImaginAb have developed an antibody fragment, known as a ‘minibody’ to scan the physical immune response status using a mapping marker known as CD8. CD8 positive T-cells (known as cytotoxic T cells) are central to our immune response to disease.
Immunotherapies work to prevent cancer cells stopping and hiding from our natural immune responses, by blocking immune checkpoints.
These ‘checkpoint inhibitors’ and next generation drugs are rapidly becoming central in the fight against cancer.
The result is an entire physical profile of a patient’s total immune status and the ability to identify response to treatment quicker.
Integrating smart imaging technology into the life science and healthcare markets with a pioneering solution.
Discover CD8 ImmunoPET Imaging and gain greater insight, clarity and patient care through pioneering body scans.
Demand more from immuno oncology biomarkers with CD8 ImmunoPET Imaging
Move from repeat painful biopsies to seeing the bigger treatment picture. CD8 ImmunoPET Imaging visualizes a patient’s real time response to treatments, resulting in increased clarity and greater care.
Entirely non-invasive and requiring no patient preparation, a thorough body scan can be created before, during or after treatment, delivering insightful data for more informed decisions.
Our CD8 ImmunoPET Imaging creates an in-depth real time profile of how a patient is responding, or not responding to a cancer treatment.
It delivers results faster, identifying whether a treatment should be continued with our stopped. This significantly reduces costs of developing new treatments while providing reassurance to patients that they are receiving the best possible treatment for them.
In the last 3 years, we have extended our operations so that we can offer clinical trials within the US, Europe and Australia.
We’re here for you at every stage with implementation support and imaging protocols IND, IRB, IB and ICF.
Our team are established industry experts, made up of commercial and operational leaders from the pharmaceutical, biotech and radiopharmaceuticals industries.
We have an extensive network of ImmunoPET Imaging sites, validated and trained for our unique CD8 imaging technology.
89Zr CD8 Immuno-PET imaging agents provide access to "highly specific and precise imaging of the presence of CD8 T Cells in solid tumors over time."
"ImaginAb shares the same patient-focused mindset and dedication to producing products of the highest quality for patients."
"We now have access to a novel and important technology that can simultaneously measure CD8+ T cells in multiple tissues, including all target and non-target tumor lesions...we have the potential to use this technology in future clinical trials to potentially expedite the development of our immuno-oncology pipeline therapies."
"Within the burgeoning field of immuno-oncology there is a clear need for better tools such as Zr-89 IAB22M2C to potentially change the clinical management of patients with cancer."
CD8 T cell imaging "will deliver information on whether the patients’ tumors are inflamed and whether they respond to treatment. This bears great potential to support better treatment decisions for the patient as well as faster selection of the best candidate compounds for the development of immuno oncologic treatments"
"With ImaginAb, we have gained a partner that is internationally pioneering in the field of immune imaging technology. Coupled with our expertise in translational imaging and radiopharmacy, we hope to make a positive contribution to improving cancer immunotherapies by means of clinical trials."